Romania

Population (January 2013):	20 020 074
Human development Index (2013):	0.785
HAV vaccine recommendations:	HAV vaccination is not included in the National Immunization Programme. HAV vaccination is utilised as an intervention measure for children in an outbreak/epidemic situation.
Seroprevalence studies by quality score:	score 0: 4 studies; score 1: 0 studies; score 2: 1 study
Seroprevalence studies timeframe:	1980–2002

Seroprevalence assessment: **intermediate** Incidence assessment: **intermediate** Risk of infection >30 years: **low**

HAV seroprevalence studies conducted in Romania over the period 1980–2002 show very similar patterns of the presence of anti-HAV antibodies in the population increasing with age. No epidemiological transition is evident over this period (Figure 1). In more details, the most recent study from Kurkela et al. (Kurkela 2012) reports a seroprevalence of 45% in children below 10; increasing to 62% in children aged 10–19, and reaching 90% in those aged 30 and older. This profile is characteristic of a country at intermediate endemicity.

Romania_Table 1. Hepatitis A seroprevalence level by time period


	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

The incidence of acute hepatitis A in Romania is available from 1990 and shows a steep decrease over the decade from almost 300/100 000 to values comprised between 50 and 100/100 000 at the turn of the century. Since 2006, incidence is reported at below 50/100 000 with a decreasing trend (Figure 2).


The susceptibility among adults is low, as susceptibility levels are below 25%.by 30 years and older


Romania_Figure 1 (panel a). Summary of seroprevalence in Romania, by age and time period

Panel a.1: 1975-1989




Panel a.2: 1990-1999





Romania_Figure 1 (panel b). Summary of seroprevalence in Romania, by age and time period (1975-2013)

Romania_Figure 2. Reported incidence of hepatitis A, Romania, 1990-2013*



*National data source: personal communication from ECDC National Focal Point/Operational Contact Point, National Institute of Public Health

Bibliography

- Iacob E, Durnea C, Nastase A, Scripcaru L, Pisica-Donose G. [Viral hepatitis A as an occupational disease in the city of Iasi]. Rev Med Chir Soc Med Nat Iasi. 1999 Jul-Dec;103(3-4):161-6.
- 2. Kurkela S, Pebody R, Kafatos G, Andrews N, Barbara C, Bruzzone B, et al. Comparative hepatitis A seroepidemiology in 10 European countries. Epidemiol Infect. 2012 Dec;140(12):2172-81.

- 3. Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, et al. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination. J Travel Med. 2007;14(3):181-7.
- 4. Onesciuc C, Szantay I, Gorgan V. The incidence of antibodies to hepatitis virus A (anti-HA) in an unselected urban population. Bacteriologia Virusologia Parazitologia Epidemiologia. 1981;26(3):167-73.
- 5. Sabau M, Golea C, Danila M, Hompoth A. The rate of infections caused by the hepatitis viruses in the Tirgu-Mures area. Bacteriologia, virusologia, parazitologia, epidemiologia (Bucharest, Romania : 1990). 1993;38(1-2):28-31.
- 6. Sabau M, Kiss E, Muntean I, Capilna E. Serologic markers of hepatitis B and A infections in the healthy population. Virologie. 1983 Jul-Sep;34(3):197-201.